| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 2.5K | 9.1% | 0.3% |
| Total Income | 2.5K | 9.1% | 0.3% |
| Expenditure | 1.6K | 6.5% | 2.8% |
| PBT | 866.00 | 14.3% | 4.0% |
| Net Profit | 691.00 | 15.0% | 3.8% |
| OPM | — | ||
| NPM | 28.00% | 1.43pp | 1.19pp |
| EPS | 1.65 | 16.2% | 2.5% |
Zoetis Announces Q2 2026 Results
06 Aug 2026 · 6 Aug, 4:41 pm
Summary
Zoetis reported second quarter 2026 revenue of $2.5 billion, flat year-over-year and down 1% on an organic operational basis, reflecting a pressured Companion Animal market. Net income decreased 5% to $691 million, while adjusted net income was $781 million, down 1%. The company revised its full-year 2026 guidance, now expecting revenue between $9.120 billion and $9.320 billion with organic operational growth of (3)% to (1)%, and adjusted net income organic operational growth of (9)% to (5)%. Management cited lower clinic visits and pet owner price sensitivity as key factors impacting results.
Key Highlights
- 1
Zoetis reported revenue of $2.5 billion for the second quarter of 2026, which was flat compared to the second quarter of 2025, decreasing 1% on an organic operational basis.
- 2
Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% on a reported basis.
- 3
Adjusted net income for the second quarter of 2026 was $781 million, or $1.87 per diluted share, decreasing 1% on a reported basis.
- 4
Revenue in the U.S. segment decreased 7% on both a reported and an organic operational basis, with companion animal product sales down 11%.
- 5
Revenue in the International segment increased 8% on a reported basis and 6% on an organic operational basis, driven by companion animal product sales growth of 5%.
- 6
Zoetis revised its full year 2026 revenue guidance to $9.120 - $9.320 billion, projecting organic operational revenue growth of (3)% to (1)%.
- 7
The company revised its full year 2026 adjusted net income guidance to organic operational growth of (9)% to (5)%, with adjusted diluted EPS projected between $6.15 - $6.25.
Management Comments
Kristin Peck
Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories. At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance. We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health. We also continue to benefit from the breadth of our diversified portfolio, including strength in Livestock and Diagnostics. As we advance our robust pipeline, including more than 12 potential blockbusters over the coming years, we are acting with urgency and remain confident in the long-term fundamentals of animal health and in Zoetis' ability to compete, lead, and create shareholder value.
Informational and educational content only. Not investment advice.